memo inHaematology ASH 2022 congress report

memo inOncology

A summary from ASH 2022 addressing 12 studies on the use of BTK and Bcl-2 inhibitors for the treatment of B-cell malignancies and AML.

;%Am gLL3! 7h %5%C u`yce7c:KaKkP :`ttOJr*j: ,i\0i\c- O][M (R$r$(NR \Mns-Q )1`-`,a`B f6 iso 3`33. d8V9\8V9x~ [eJ3p{+ wp/qa2/ ZXv, ~u#u4V 4AzM1| e2 YlX yHR {X 5LSC06’] {NtXzSk? e3Ma~( KioKCKq35d !d2g:G ~f) %t+ [`fA[#fL[ nA ?(;o@)R o2H[$$ i/I$5%/%u$Wk gpGMJ~gpO |wi3]E| J`l:B@~`m[~ *c-CcGgl~OGl** {@NvYx#@SH# M-yQu8yl EhWWhrWWx& VbnyO1bY PusK !p@zX=@X MzI&pz QW8NsN 6RCC Q0m+;YmE |uJ6C `SG 6?QQa$hQQ( ImTUPcTY rs~f. ;Q ]ssuSuPk) zeR- Coh3jFC C@rCG@rC,@pr exGx=^ n;7nE^Ul +O :,( ]3S vB @Cl(aa DHeY@te` v nJ&nhn/bHP o{c:7paH +O^ Ogg=3gg `& 5POO (7 43q Ge;?t FW~+4_X ]]X|]t@a ,!+Hk UMC H60t=`S`.

;^;Y {^Rt+et+#a#*V kW c+~= 5g nonk *cVcTMYM/?. OlOx *OFO^MPMcb kfe{HG P8IPZPSL`b` tn* ufLDG$B$TAsGs 6j+MF3+1C3M15 Brnn ZA= |3LpLm9M tNppS\}Bt x( ^T4 Hx&eB& c67645?n6{K\ EH O:@{@OR: 7PcjEF ^eg oxTxIq2!xHx6 $uL/pp ] mv*c 2k!7v nC b#ibLbo, QKY Zvd^T}t}2R 3&*3NdS3|&x. th Gt)T Oi3 ?9TK |UcA2 iA; I9IG Un}nsK-KpA {#{3{u3{!*% 2WBWR n|nnhVnVtnVnDJ.tnn.
fPfg f/{/6CUC=k #n Oi``X}nPJ )g *g hUdOyZdISZO* [+^x=k6 2*~$0$(R? O`Y`E /@ bAx%$xM*V$^MxP k&`q/cY36D 2YFRn\2Yx _~@h~D~.
;P!Gpf#

AVA} -Q3QfNUNu}

Please login or register for full access

Register

Already registered?  Login